Moderna Clears Legal Hurdle With $2.25 Billion Patent Settlement

Moderna has agreed to pay up to $2.25 billion to settle a patent dispute over the technology used in its COVID-19 vaccine. The agreement resolves lawsuits filed by Genevant Sciences and Arbutus Biopharma, which accused Moderna of using their lipid nanoparticle delivery technology without authorization, according to Investing.com.

Moderna has agreed to pay Roivant up to $2.25 billion to settle claims that the mRNA vaccine developer infringed on Roivant’s patents in its Covid-19 shot. https://t.co/VT3Dn4YVhn

— STAT (@statnews) March 4, 2026

The settlement ends legal battles in the United States and internationally. Analysts at William Blair said the resolution removes uncertainty for Moderna as the company prepares for several late stage oncology trial results expected in 2026.

Also Read:

Why Is CIA Exploring Plan To Arm Kurdish Forces Against Iran

The CIA is reportedly exploring plans to arm Kurdish opposition groups in an effort to pressure Iran’s government and potentially spark an uprising, according to CNN. U.S. officials have held discussions with Iranian Kurdish factions and leaders in Iraq about providing military support as the conflict with Tehran

tippinsightsTIPP Staff